Globus Medical Cuts 2026 Revenue Outlook To $3.09 Billion, And Its CEO Points At Company Execution
CEO Keith Pfeil blamed delayed launches and weak rep recruiting, not the market, for a third quarter that cut guidance from $3.18 billion to $3.22 billion.
Globus Medical CEO Keith Pfeil said on the company's Thursday earnings call that delayed product launches and weak competitive rep recruiting, not a soft market, explain a third quarter that led the company to cut its 2026 revenue forecast to $3.09 billion. The previous range was $3.18 billion to $3.22 billion, CFO Kyle Klin said.
A CEO who won't blame the market
Globus Medical, a Pennsylvania-based maker of spine, orthopedic and neurosurgical devices and surgical robots, reported third-quarter revenue of $763.7 million, down 0.7% as reported. Adjusted earnings were $1.23 a share, up 4%.
Asked by a Jefferies analyst about market slowness that a competitor had flagged, Pfeil said he would "shy away from that." He added: "there's things that we could have done better to achieve the growth that we thought we were going to get."
Pressed by a BMO Capital Markets analyst on what the delays cost, Pfeil said, "I'm not going to break out the parts of the Q3 revenue miss." He pointed to launch timing and weaker competitive rep growth.
On recruiting, he said last year's recruits brought over large dollar amounts, creating a bigger base to grow from. The shortfall only became visible in mid-September: "I didn't see that bounce back."
What the lower guide implies
Klin said the new outlook implies a mid-single-digit decline in the fourth quarter. He cited three drivers: spine launches pushed into 2027, with no meaningful 2026 contribution from the Scrip implants or the prone positioner; a Nevro recovery in which trial volumes have not returned to target; and a tough comparison in enabling technologies as the company shifts toward rental and lease deals.
Globus kept its adjusted earnings guidance at $4.95 to $5.05 a share.
The base business excluding Nevro grew 3% to $690 million. Nevro, the pain-therapy business Globus bought, fell 25.7% to $73.7 million. U.S. spine rose 2%, enabling technologies grew 24% to $34.9 million, and trauma rose 19%.
Free cash flow was a record $225 million. The company bought back 1.9 million shares for $143 million, and its board added $500 million to the repurchase program.
Launches and 2027
Scrip is available now. The X-Lift prone positioner and two-blade retractor are due later this quarter, and a new Nevro pulse generator, HFX Elite, is slated for a first-half 2027 launch.
Pressed by a Bank of America analyst on whether the Street's 6% organic growth estimate for 2027 was reasonable, Pfeil said, "Not guiding on 27 yet." He said mid to high single-digit revenue growth is where Globus would like to be.
Pfeil said both small third-quarter acquisitions, Higgs-Boson and the Synaptive assets, are not yet producing revenue and are not expected to be meaningful contributors in 2027.
Sources
- Globus Medical lowers 2026 revenue outlook to $3.09B while reiterating non-GAAP EPS of $4.95-$5.05 (NYSE:GMED) | Seeking Alpha — seekingalpha.com
- Globus Medical (GMED) Q3 Earnings Top Estimates — Yahoo Finance
- Globus Medical Non-GAAP EPS of $1.23 beats by $0.03, revenue of $763.7M misses by $28.76M (GMED:NYSE) | Seeking Alpha — seekingalpha.com
- Compared to Estimates, Globus Medical (GMED) Q3 Earnings: A Look at Key Metrics — Yahoo Finance
- Globus Medical: Q3 Earnings Snapshot | wusa9.com — Associated Press